Smith & Nephew stock (GB0009223206): Cevian Capital boosts stake above 11%

Activist investor Cevian Capital has increased its stake in Smith & Nephew above 11%, signaling potential strategic interest in the medical devices firm amid recent upbeat guidance.

Smith & Nephew shares drew attention as activist investor Cevian Capital lifted its stake above 11%, according to TipRanks as of recent filing. This move comes alongside the company's recent earnings call, which featured optimistic 2026 growth and profit guidance despite near-term tariff headwinds.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Smith & Nephew plc
• Sector/industry: Medical Devices
• Headquarters/country: United Kingdom
• Core markets: Orthopedics, sports medicine, wound care
• Home exchange/listing venue: NYSE (SNN), London Stock Exchange
• Trading currency: USD, GBP

Smith & Nephew: core business model

Smith & Nephew plc develops and markets medical devices focused on orthopaedics, sports medicine, and advanced wound management. The company serves hospitals and clinics globally, with a strong presence in advanced surgical solutions. Its portfolio includes hip and knee implants, endoscopic devices, and bioactive wound dressings, addressing high-volume procedures in aging populations.

Listed on the NYSE under ticker SNN with ISIN GB0009223206, Smith & Nephew offers US investors exposure to the growing medtech sector. The firm reported a market cap around $13.19 billion as of data published in 2026 by WallStreetZen for 2026.

Main revenue and product drivers for Smith & Nephew

Orthopaedics forms a key revenue pillar, driven by joint reconstruction systems amid rising demand for knee and hip replacements in the US and Europe. Sports medicine contributes through arthroscopy products, while wound care leverages regenerative technologies. Recent earnings highlighted growth potential into 2026, per the company's call referenced in TipRanks coverage.

Dividend sustainability stands out, with a 2.56% yield above the medical device industry average of 1.36%, based on 2026 analysis from WallStreetZen for 2026. The payout ratio of 52.8% supports long-term stability despite past fluctuations.

Why Smith & Nephew matters for US investors

With an NYSE listing, Smith & Nephew provides US retail investors direct access to a leading UK medtech player with substantial US revenue exposure. The sector benefits from demographic trends like an aging population driving procedure volumes. Cevian's stake increase underscores confidence amid tariff concerns flagged in recent guidance.

Industry trends and competitive position

The global bunion correction systems market highlights Smith & Nephew as a top competitor due to its orthopedic innovations, per Spherical Insights outlook for 2026-2035. Competitors include Stryker and Zimmer Biomet, but Smith & Nephew's diversified portfolio aids resilience.

Conclusion

Cevian Capital's stake hike above 11% highlights investor interest in Smith & Nephew amid positive 2026 guidance. The company's strong dividend profile and medtech positioning offer relevant exposure for US portfolios, though tariff risks warrant monitoring. Market dynamics in orthopedics continue to shape its trajectory.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.